Cited 0 times in
The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 강석구 | - |
dc.contributor.author | 김세훈 | - |
dc.contributor.author | 김의현 | - |
dc.contributor.author | 윤홍인 | - |
dc.contributor.author | 장종희 | - |
dc.contributor.author | 조재호 | - |
dc.date.accessioned | 2019-09-20T07:35:50Z | - |
dc.date.available | 2019-09-20T07:35:50Z | - |
dc.date.issued | 2019 | - |
dc.identifier.issn | 2288-2405 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/170970 | - |
dc.description.abstract | BACKGROUND: There has been no practical guidelines for the management of patients with central nervous system (CNS) tumors in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, started to prepare guidelines for CNS tumors from February 2018. METHODS: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified through searches of PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL using specific and sensitive keywords as well as combinations of keywords. RESULTS: First, the maximal safe resection if feasible is recommended. After the diagnosis of a glioblastoma with neurosurgical intervention, patients aged ≤70 years with good performance should be treated by concurrent chemoradiotherapy with temozolomide followed by adjuvant temozolomide chemotherapy (Stupp's protocol) or standard brain radiotherapy alone. However, those with poor performance should be treated by hypofractionated brain radiotherapy (preferred)±concurrent or adjuvant temozolomide, temozolomide alone (Level III), or supportive treatment. Alternatively, patients aged >70 years with good performance should be treated by hypofractionated brain radiotherapy+concurrent and adjuvant temozolomide or Stupp's protocol or hypofractionated brain radiotherapy alone, while those with poor performance should be treated by hypofractionated brain radiotherapy alone or temozolomide chemotherapy if the patient has methylated MGMT gene promoter (Level III), or supportive treatment. CONCLUSION: The KSNO's guideline recommends that glioblastomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to the individual comprehensive condition of the patient. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Korean Brain Tumor Society | - |
dc.relation.isPartOf | Brain Tumor Research and Treatment | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | The Korean Society for Neuro-Oncology (KSNO) Guideline for Glioblastomas: Version 2018.01 | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Neurosurgery (신경외과학교실) | - |
dc.contributor.googleauthor | Young Zoon Kim | - |
dc.contributor.googleauthor | Chae-Yong Kim | - |
dc.contributor.googleauthor | Jaejoon Lim | - |
dc.contributor.googleauthor | Kyoung Su Sung | - |
dc.contributor.googleauthor | Jihae Lee | - |
dc.contributor.googleauthor | Hyuk-Jin Oh | - |
dc.contributor.googleauthor | Seok-Gu Kang | - |
dc.contributor.googleauthor | Shin-Hyuk Kang | - |
dc.contributor.googleauthor | Doo-Sik Kong | - |
dc.contributor.googleauthor | Sung Hwan Kim | - |
dc.contributor.googleauthor | Se-Hyuk Kim | - |
dc.contributor.googleauthor | Se Hoon Kim | - |
dc.contributor.googleauthor | Yu Jung Kim | - |
dc.contributor.googleauthor | Eui Hyun Kim | - |
dc.contributor.googleauthor | In Ah Kim | - |
dc.contributor.googleauthor | Ho Sung Kim | - |
dc.contributor.googleauthor | Tae Hoon Roh | - |
dc.contributor.googleauthor | Jae-Sung Park | - |
dc.contributor.googleauthor | Hyun Jin Park | - |
dc.contributor.googleauthor | Sang Woo Song | - |
dc.contributor.googleauthor | Seung Ho Yang | - |
dc.contributor.googleauthor | Wan-Soo Yoon | - |
dc.contributor.googleauthor | Hong In Yoon | - |
dc.contributor.googleauthor | Soon-Tae Lee | - |
dc.contributor.googleauthor | Sea-Won Lee | - |
dc.contributor.googleauthor | Youn Soo Lee | - |
dc.contributor.googleauthor | Chan Woo Wee | - |
dc.contributor.googleauthor | Jong Hee Chang | - |
dc.contributor.googleauthor | Tae-Young Jung | - |
dc.contributor.googleauthor | Hye Lim Jung | - |
dc.contributor.googleauthor | Jae Ho Cho | - |
dc.contributor.googleauthor | Seung Hong Choi | - |
dc.contributor.googleauthor | Hyoung Soo Choi | - |
dc.contributor.googleauthor | Je Beom Hong | - |
dc.contributor.googleauthor | Do Hoon Lim | - |
dc.contributor.googleauthor | Dong-Sup Chung | - |
dc.identifier.doi | 10.14791/btrt.2019.7.e25 | - |
dc.contributor.localId | A00036 | - |
dc.contributor.localId | A00610 | - |
dc.contributor.localId | A00837 | - |
dc.contributor.localId | A04777 | - |
dc.contributor.localId | A03470 | - |
dc.contributor.localId | A03901 | - |
dc.relation.journalcode | J00398 | - |
dc.identifier.eissn | 2288-2413 | - |
dc.identifier.pmid | 31062525 | - |
dc.subject.keyword | Glioblastomas | - |
dc.subject.keyword | Guideline | - |
dc.subject.keyword | Korean Society for Neuro-Oncology | - |
dc.subject.keyword | Practice | - |
dc.contributor.alternativeName | Kang, Seok Gu | - |
dc.contributor.affiliatedAuthor | 강석구 | - |
dc.contributor.affiliatedAuthor | 김세훈 | - |
dc.contributor.affiliatedAuthor | 김의현 | - |
dc.contributor.affiliatedAuthor | 윤홍인 | - |
dc.contributor.affiliatedAuthor | 장종희 | - |
dc.contributor.affiliatedAuthor | 조재호 | - |
dc.citation.volume | 7 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.identifier.bibliographicCitation | Brain Tumor Research and Treatment, Vol.7(1) : 1-9, 2019 | - |
dc.identifier.rimsid | 64862 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.